Inventor · disambiguated record
Frank Rigo
Also filed as: RIGO FRANK
50 granted patents·59 pending applications·284 citations·filing 2010–2025
98Inventor score
Files withIONIS PHARMACEUTICALS INC85BIOGEN MA INC11COLD SPRING HARBOR LABORATORY4ISIS PHARMACEUTICALS INC2BENNETT C FRANK1
Top patents by PatentIndex Score
109 records- 0197US11299737B1Compounds and methods for modulating SMN2IONIS PHARMACEUTICALS INC·Filed 2021·Granted Apr 12, 2022·3 cites·32 claims
- 0297US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0397US9605263B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·20 cites·20 claims
- 0497US8980853B2Compositions and methods for modulation of SMN2 splicing in a subjectBENNETT C FRANK·Filed 2010·Granted Mar 17, 2015·48 cites·4 claims
- 0594US10538763B2Compounds and methods for modulation of DUX4IONIS PHARMACEUTICALS INC·Filed 2016·Granted Jan 21, 2020·21 cites·17 claims
- 0694US10138482B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 27, 2018·11 cites·20 claims
- 0794US9926559B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2014·Granted Mar 27, 2018·12 cites·10 claims
- 0893US10815483B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Oct 27, 2020·4 cites·20 claims
- 0992US10436802B2Methods for treating spinal muscular atrophyBIOGEN MA INC·Filed 2015·Granted Oct 8, 2019·13 cites·20 claims
- 1092US10221414B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted Mar 5, 2019·14 cites·34 claims
- 1191US10407678B2Compositions for modulating expression of C9ORF72 antisense transcriptIONIS PHARMACEUTICALS INC·Filed 2015·Granted Sep 10, 2019·6 cites·35 claims
- 1290US11926825B2Compounds and methods for reducing ATXN2 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Mar 12, 2024·1 cites·26 claims
- 1390US9644207B2Compositions and methods for modulating Tau expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted May 9, 2017·10 cites·26 claims
- 1489US11339393B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted May 24, 2022·2 cites·33 claims
- 1589US9963699B2Methods for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2013·Granted May 8, 2018·22 cites·28 claims
- 1688US12188020B2Methods for reducing Ataxin-2 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Jan 7, 2025·1 cites·45 claims
- 1787US9518259B2Compounds and methods for modulating interaction between proteins and target nucleic acidsRIGO FRANK·Filed 2011·Granted Dec 13, 2016·19 cites·14 claims
- 1887US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 1986US11535848B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2020·Granted Dec 27, 2022·1 cites·12 claims
- 2086US10344282B2Compositions and methods for modulation of IKBKAP splicingIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 9, 2019·2 cites·20 claims
- 2185US11732260B2Compounds and methods for the modulation of amyloid-β precursor proteinIONIS PHARMACEUTICALS INC·Filed 2019·Granted Aug 22, 2023·2 cites·39 claims
- 2285US9617539B2Modulation of UBE3A-ATS expressionIONIS PHARMACEUTICALS INC·Filed 2013·Granted Apr 11, 2017·17 cites·16 claims
- 2385US2025179493A1Compounds and methods for modulating smn2IONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2484US11058709B1Methods of treating breast cancerCOLD SPRING HARBOR LABORATORY·Filed 2016·Granted Jul 13, 2021·4 cites·15 claims
- 2584US10533175B2Compositions and methods for modulating Ataxin 3 expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Jan 14, 2020·3 cites·54 claims
- 2684US9353371B2Antisense compounds targeting genes associated with usher syndromeHASTINGS MICHELLE L·Filed 2012·Granted May 31, 2016·5 cites·15 claims
- 2783US2025283081A1Compounds and Methods for Modulating UBE3A-ATSIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2882US12275940B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2023·Granted Apr 15, 2025·0 cites·18 claims
- 2982US11155815B2Compositions and methods for modulating Tau expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Oct 26, 2021·1 cites·33 claims
- 3082US2025354147A1Antisense Compounds Targeted to CLN3 and Uses ThereofIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3181US11786546B2Compounds and methods for modulating GFAPIONIS PHARMACEUTICALS INC·Filed 2020·Granted Oct 17, 2023·1 cites·42 claims
- 3281US11781135B2Methods for treating Alzheimer's diseaseWASHINGTON UNIVERSITY ST LOUIS·Filed 2019·Granted Oct 10, 2023·1 cites·38 claims
- 3380US11725208B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2018·Granted Aug 15, 2023·1 cites·33 claims
- 3480US10273474B2Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndromeUNIV WASHINGTON·Filed 2013·Granted Apr 30, 2019·4 cites·17 claims
- 3580US2025304970A1Methods for Reducing Ataxin-2 ExpressionIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3680US2024401039A1Compounds and Methods for Reducing ATXN2 ExpressionIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3779US11198867B2Combinations for the modulation of SMN expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Dec 14, 2021·2 cites·37 claims
- 3879US2023183696A1Compositions and Methods for Modulation of SMN2 Splicing in a SubjectBIOGEN MA INC·Filed 2022·Application pending·0 cites
- 3978US12502402B2Compounds and methods for modulating GFAPIONIS PHARMACEUTICALS INC·Filed 2023·Granted Dec 23, 2025·0 cites·42 claims
- 4078US10793855B2Compositions for modulating expression of C9ORF72 antisense transcriptIONIS PHARMACEUTICALS INC·Filed 2016·Granted Oct 6, 2020·1 cites·42 claims
- 4177US11162096B2Methods for modulating expression of C9ORF72 antisense transcriptIONIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 2, 2021·1 cites·27 claims
- 4277US11033570B2Modulation of Lnc05 expressionCOLD SPRING HARBOR LABORATORY·Filed 2017·Granted Jun 15, 2021·2 cites·13 claims
- 4377US9828602B2Antisense compounds targeting genes associated with fibronectinIONIS PHARMACEUTICALS INC·Filed 2013·Granted Nov 28, 2017·1 cites·9 claims
- 4475US10400243B2Modulation of UBE3A-ATS expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Sep 3, 2019·2 cites·28 claims
- 4575US2020376018A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 4674US2024287513A1Compounds and Methods for Modulating Splicing of Pre-MRNAIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4773US2023112920A1Compositions for Modulating C9ORF72 ExpressionIONIS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4873US2022243200A1Compositions and methods for modulating tau expressionIONIS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4973US2024335556A1Compounds and Methods for Reducing DMPK ExpressionIONIS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 5072US11833221B2Oligomeric compounds for reducing DMPK expressionIONIS PHARMACEUTICALS INC·Filed 2022·Granted Dec 5, 2023·0 cites·30 claims
Showing the top 50 of 109 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Frank Rigo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →